Home Compare BIIB vs GILD
Stock Comparison · Industry comparison · Drug Manufacturers - General

Biogen vs Gilead Sciences: Which Stock Looks Stronger in 2026?

Gilead Sciences holds the cleaner structural position, with the lead spread across profitability and stability. Biogen does not offset that deficit through any equally strong structural edge elsewhere. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest separation starts in profitability, but stability adds another real layer to the result. Gilead Sciences, Inc. leads by 44 points on the overall comparison score.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. BIIB and GILD share the same industry classification.

For a similarity-based comparison, see how Biogen and Gilead Sciences each position within their functional peer groups in AssetNext.

Peer-Relative Score
BIIB
Biogen Inc.
26
Peer-Score
Signal qualityHigh
vs
GILD
Gilead Sciences, Inc.
70
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: BIIB vs GILD Profitability 0 79 Stability 10 65 Valuation 80 83 Growth 0 44 BIIB GILD
Gap Ranking
#1 Profitability +79
#2 Stability +55
#3 Growth +44
#4 Valuation +3
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for BIIB and GILD Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer BIIBGILD Relative valuation Structural strength

The setup stays mixed because structure and the price setup do not align cleanly in one direction.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Profitability
On profitability, Gilead Sciences, Inc. ranks near the top of the group; Biogen Inc. sits in the weaker half.
Stability
The same broad pattern appears on stability: Gilead Sciences, Inc. ranks near the top of the group, while Biogen Inc. stays in the weaker half.
Profitability — Dominant Gap
BIIB
0
GILD
79
Gap+79in favour of GILD

The profitability lead is mainly driven by a 17.7-point operating margin advantage.

What else supports the lead

Stability still reinforces the same direction, which makes the lead look broader across the profile.

What this means for the comparison

The lead is built on both profitability and stability, making it broader than a single-dimension result.

Explore full peer positioning in AssetNext

Break down the BIIB vs GILD comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar profitability-and-stability comparisons

Explore how BIIB and GILD each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.